ad-sphingolipid-ceramide-companies

📖 Wiki Page

company1838 wordssynced 2026-04-02

[Alzheimer's disease](/diseases/alzheimers-disease) Sphingolipid and Ceramide Signaling Therapy Companies

Overview

flowchart TD companies_ad_sphingolipid_cera["ad-sphingolipid-ceramide-companies"] style companies_ad_sphingolipid_cera fill:#4fc3f7,stroke:#333,color:#000 companies_ad_sphingo_0["Key Companies"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_0 style companies_ad_sphingo_0 fill:#81c784,stroke:#333,color:#000 companies_ad_sphingo_1["Ceramide Modulators"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_1 style companies_ad_sphingo_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_sphingo_2["Ganglioside and Glycosphingolipid Approaches"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_2 style companies_ad_sphingo_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_sphingo_3["Lipid Nanoparticle and Delivery Technologies"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_3 style companies_ad_sphingo_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_sphingo_4["Multi-Mechanism Approaches"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_4 style companies_ad_sphingo_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_sphingo_5["Scientific Background"] companies_ad_sphingolipid_cera -->|"includes"| companies_ad_sphingo_5 style companies_ad_sphingo_5 fill:#81c784,stroke:#333,color:#000

...

[Alzheimer's disease](/diseases/alzheimers-disease) Sphingolipid and Ceramide Signaling Therapy Companies

Overview

Mermaid diagram (expand to render)

Sphingolipids are essential structural and signaling molecules in the [brain](/brain-regions/brain), constituting a major component of neuronal and [glial cells](/cell-types/astrocytes) membranes. Ceramide — the central hub of sphingolipid metabolism — plays critical roles in regulating [apoptosis](/mechanisms/apoptosis-pathway), neuroinflammation, amyloid processing, and synaptic function. [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease) ([Alzheimer's disease](/diseases/alzheimers-disease)), alterations in sphingolipid metabolism are emerging as key drivers of pathology, with [ceramide](/proteins/ceramide) levels elevated in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s and linked to neuronal death, [amyloid-beta](/proteins/amyloid-beta) production, and [[microglia](/cell-types/microglia)](/cell-types/microglia) activation.

The therapeutic targeting of sphingolipid pathways represents a novel approach to [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease) that addresses multiple disease mechanisms simultaneously. Key mechanisms include:

Ceramide-mediated [apoptosis](/mechanisms/apoptosis-pathway): Elevated [ceramide](/proteins/ceramide) promotes neuronal [apoptosis](/mechanisms/apoptosis-pathway) through caspase activation and [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
Lipid raft disruption: Alterations in membrane sphingolipid composition affect [amyloid precursor protein](/proteins/app) (APP) processing and [amyloid-beta](/proteins/amyloid-beta) production
Neuroinflammation: Ceramide activates pro-inflammatory pathways in [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes)
Autophagy dysregulation: Sphingolipid accumulation impairs [autophagosome-lysosome fusion](/mechanisms/[autophagy](/mechanisms/autophagy-lysosome-pathway)-lysosome-pathway)
Synaptic dysfunction: Ganglioside alterations disrupt [synaptic vesicle](/mechanisms/synaptic-vesicle-trafficking) trafficking and receptor signaling

This category covers companies developing small molecules, biologics, and novel delivery technologies targeting sphingolipid metabolism and [ceramide](/proteins/ceramide) signaling in [Alzheimer's disease](/diseases/alzheimers-disease).

Key Companies

Ceramide Modulators

Cyclo Therapeutics

Focus: Heat Shock Protein 90 ([HSP90](/proteins/hsp90)) inhibitors with sphingolipid modulation activity
Lead Candidate: Trappsol (cyclodextrin) — Phase 3 in Niemann-Pick Type C, being explored in [Alzheimer's disease](/diseases/alzheimers-disease)
Indication: [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical/Phase 1 planning), NPC disease
Mechanism: Cyclodextrin-based sequestration of [cholesterol](/proteins/cholesterol) and sphingolipids, enhancing [lysosomal](/mechanisms/lysosomal-dysfunction) function and reducing glycosphingolipid accumulation. Demonstrated reduction of amyloid-beta plaques in [Alzheimer's disease](/diseases/alzheimers-disease) mouse models.
Pipeline: Trappsol administered intravenously, with clinical trials in [Alzheimer's disease](/diseases/alzheimers-disease) expected to initiate in 2025-2026
Notable: Cyclodextrins have been shown to mobilize [cholesterol](/proteins/cholesterol) and sphingolipids from [lysosomal](/mechanisms/lysosomal-dysfunction) storage, potentially improving neuronal clearance mechanisms

Axxonis Pharma

Focus: Sphingolipid signaling pathway modulators
Indication: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease) (preclinical)
Mechanism: Develops small molecules targeting [ceramide](/proteins/ceramide) synthases (CerS) and [sphingosine kinase](/proteins/sphingosine-kinase)s (SK1/SK2). Key targets include:
Ceramide synthase 1 (CerS1) — converts sphingosine to C18-[ceramide](/proteins/ceramide), elevated in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s
Sphingosine-1-phosphate (S1P) receptor modulators — S1P drives neuroinflammation
Acid ceramidase inhibitors — reduce pro-survival [ceramide](/proteins/ceramide) catabolism
Stage: Preclinical development, lead optimization
Scientific Foundation: Founded by researchers from the [Van Andel Institute](/organizations/van-andel-institute) with deep expertise in sphingolipid biochemistry and neurodegenerative disease

Accerise

Focus: Ceramide metabolism modulators
Indication: [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical)
Mechanism: Develops small molecule inhibitors of [acid ceramidase](/proteins/acid-ceramidase) (ASAH1) and [ceramide](/proteins/ceramide) galactosyltransferase (CGT). Reducing ceramidase activity increases endogenous [ceramide](/proteins/ceramide) levels for [neuroprotection](/therapeutics/neuroprotection) signaling while inhibiting CGT reduces galactocerebroside accumulation.
Stage: Lead optimization
Notable: Focuses on the balance between pro-apoptotic long-chain [ceramide](/proteins/ceramide)s (C16-C24) and [neuroprotection](/therapeutics/neuroprotection) very-long-chain [ceramide](/proteins/ceramide)s (C26+)

Ganglioside and Glycosphingolipid Approaches

Esperino Therapeutics

Focus: Ganglioside-based [neuroprotection](/therapeutics/neuroprotection) therapies
Indication: [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical)
Mechanism: Develops modified ganglioside derivatives (GD3, GM1 analogs) that protect [neurons](/cell-types/neurons) from amyloid-beta toxicity and [oxidative stress](/mechanisms/oxidative-stress). Gangliosides are sialic acid-containing glycosphingolipids critical for synaptic function and neuronal membrane stability.
Stage: Preclinical, with IND-enabling studies ongoing
Scientific Rationale: GM1 ganglioside levels are reduced in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s, and GM1 administration has shown [neuroprotection](/therapeutics/neuroprotection) effects in animal models

Cerenis Therapeutics

Focus: [HDL](/proteins/hdl-particle)-based sphingolipid therapies ([ceramide](/proteins/ceramide)-rich [HDL](/proteins/hdl-particle) particles)
Indication: [Alzheimer's disease](/diseases/alzheimers-disease), cardiovascular disease
Mechanism: Develops engineered high-density lipoprotein ([HDL](/proteins/hdl-particle)) particles loaded with anti-inflammatory sphingolipids. These [ceramide](/proteins/ceramide)-rich [HDL](/proteins/hdl-particle) therapeutics are designed to reduce neuroinflammation and improve [cholesterol](/proteins/cholesterol) efflux from the [brain](/brain-regions/brain).
Stage: Preclinical
Notable: Leverages the natural role of [HDL](/proteins/hdl-particle) in reverse [cholesterol](/proteins/cholesterol) transport and sphingolipid homeostasis

Lipid Nanoparticle and Delivery Technologies

2seventy Bio

Focus: Lipid nanoparticle (LNP) delivery for CNS targeting of sphingolipid-modifying agents
Indication: Various CNS disorders, including [Alzheimer's disease](/diseases/alzheimers-disease)
Mechanism: Using their proprietary LNP platform to deliver [mRNA](/technologies/mrna-delivery) or small interfering RNA ([siRNA](/technologies/sirna-delivery)) targeting sphingolipid metabolic enzymes. For example:
[siRNA](/technologies/sirna-delivery) against glucosyl[ceramide](/proteins/ceramide) synthase (GCS) to reduce glycosphingolipid accumulation
[mRNA](/technologies/mrna-delivery) encoding functional [GCase](/proteins/gcase-glucocerebrosidase) (glucocerebrosidase) for enzyme replacement
[siRNA](/technologies/sirna-delivery) against [ceramide](/proteins/ceramide) synthase 2 (CerS2) to reduce very-long-chain [ceramide](/proteins/ceramide) accumulation
Stage: Preclinical platform validation
Notable: Their LNP technology enables CNS penetration following peripheral administration, addressing a key delivery challenge for sphingolipid-targeted therapies

Orgenesis

Focus: Autologous cell-based therapies and locoregional delivery of sphingolipid-modulating agents
Indication: [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical/early clinical)
Mechanism: Uses a proprietary closed manufacturing system to produce autologous therapeutic cells that secrete sphingolipid-modulating factors. Cell therapy approach enables sustained, localized delivery of bioactive molecules to the [brain](/brain-regions/brain).
Stage: Preclinical
Notable: Focus on locoregional (e.g., intra-nasal) delivery to bypass the blood-[brain](/brain-regions/brain) barrier

Multi-Mechanism Approaches

Gain Therapeutics

Focus: Allosteric [GCase](/proteins/gcase-glucocerebrosidase) modulators with sphingolipid effects
Lead Candidate: GT-02287
Indication: [Parkinson's disease](/diseases/parkinsons-disease) (Phase 1b), [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical)
Mechanism: Allosteric small molecule chaperones that stabilize misfolded glucocerebrosidase ([GCase](/proteins/gcase-glucocerebrosidase)), enhancing [lysosomal](/mechanisms/lysosomal-dysfunction) enzyme activity and reducing accumulation of glucosyl[ceramide](/proteins/ceramide) and related glycosphingolipids. [GCase](/proteins/gcase-glucocerebrosidase) catalyzes hydrolysis of glucosyl[ceramide](/proteins/ceramide) to [ceramide](/proteins/ceramide) — its dysfunction leads to glycosphingolipid accumulation that disrupts membrane rafts and APP processing.
Pipeline: GT-02287 in Phase 1b for [Parkinson's disease](/diseases/parkinsons-disease); [Alzheimer's disease](/diseases/alzheimers-disease) indication in preclinical development
Notable: Glucosyl[ceramide](/proteins/ceramide) accumulation alters [lipid raft](/mechanisms/lipid-raft-dysfunction) composition, affecting amyloidogenic APP processing and promoting [amyloid-beta](/proteins/amyloid-beta) production

Heqix Therapeutics

Focus: Lipid raft stabilizers targeting [GCase](/proteins/gcase-glucocerebrosidase) and sphingolipid pathways
Indication: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease)
Mechanism: Develops small molecules that stabilize [lipid raft](/mechanisms/lipid-raft-dysfunction) microdomains by modulating glycosphingolipid-to-[ceramide](/proteins/ceramide) ratios. This restores proper membrane organization, improving [GCase](/proteins/gcase-glucocerebrosidase) activity and reducing amyloid-beta generation through non-amyloidogenic APP processing.
Stage: Preclinical
Notable: Focuses on the intersection of [GCase](/proteins/gcase-glucocerebrosidase) dysfunction and [lipid raft](/mechanisms/lipid-raft-dysfunction) disruption in neurodegeneration

HAXXES

Focus: Sphingolipid-targeted antibody therapeutics
Indication: [Alzheimer's disease](/diseases/alzheimers-disease) (preclinical)
Mechanism: Develops monoclonal antibodies targeting specific sphingolipid antigens (e.g., anti-ganglioside GD3 antibodies) to modulate neuroinflammation and promote clearance of sphingolipid-rich plaques. Antibodies offer high specificity for targeting individual sphingolipid species involved in [Alzheimer's disease](/diseases/alzheimers-disease) pathology.
Stage: Preclinical, lead antibody characterization

Scientific Background

Sphingolipid Metabolism in [Alzheimer's disease](/diseases/alzheimers-disease)

Sphingolipid metabolism is profoundly altered in [Alzheimer's disease](/diseases/alzheimers-disease). The central pathway involves:

Sphingomyelin hydrolysis: Acid sphingomyelinase (ASM) converts sphingomyelin to [ceramide](/proteins/ceramide) — ASM activity is elevated in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s

Ceramide synthesis: Ceramide synthases (CerS1-6) produce distinct [ceramide](/proteins/ceramide) species with different chain lengths and functions

Ceramide signaling: Ceramide acts as a second messenger, activating protein phosphatases (PP1, PP2A) and kinases (PKCzeta, CDK5) that regulate tau phosphorylation

Sphingosine conversion: Ceramide can be metabolized to sphingosine by ceramidases, then to S1P by [sphingosine kinase](/proteins/sphingosine-kinase)s

S1P signaling: S1P promotes neuroinflammation through S1P receptor activation on microglia and astrocytes

Key Therapeutic Targets

| Target | Role in [Alzheimer's disease](/diseases/alzheimers-disease) | Therapeutic Strategy |
|--------|-----------|---------------------|
| Acid ceramidase | Converts [ceramide](/proteins/ceramide) to sphingosine (pro-survival) | Inhibitors to increase pro-apoptotic [ceramide](/proteins/ceramide) |
| Ceramide synthase 1 | Produces C18-[ceramide](/proteins/ceramide), elevated in [Alzheimer's disease](/diseases/alzheimers-disease) | Inhibitors to reduce neuronal [ceramide](/proteins/ceramide) |
| Acid sphingomyelinase | Generates [ceramide](/proteins/ceramide) from sphingomyelin | Inhibitors to reduce [ceramide](/proteins/ceramide) accumulation |
| Glucosyl[ceramide](/proteins/ceramide) synthase | Produces glucosyl[ceramide](/proteins/ceramide) from [ceramide](/proteins/ceramide) | Inhibitors to reduce glycosphingolipids |
| Ganglioside GM1 | Reduced in [Alzheimer's disease](/diseases/alzheimers-disease), synaptic dysfunction | GM1 analogs, replacements |
| S1P receptors | Pro-inflammatory signaling | S1P receptor modulators (fingolimod analogs) |
| [HSP90](/proteins/hsp90) | Stabilizes sphingolipid enzymes | [HSP90](/proteins/hsp90) inhibitors |
| Lipid rafts | APP processing microdomains | Lipid raft stabilizers |

Clinical Evidence

Elevated [brain](/brain-regions/brain) [ceramide](/proteins/ceramide) levels have been documented in post-mortem [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s, correlating with disease severity. Specific observations:

Ceramide species: C16-[ceramide](/proteins/ceramide) and C18-[ceramide](/proteins/ceramide) are significantly elevated in [Alzheimer's disease](/diseases/alzheimers-disease) prefrontal cortex
Glucosyl[ceramide](/proteins/ceramide): Accumulates in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s, particularly in [neurons](/cell-types/neurons) with tau pathology
GM1 ganglioside: Reduced by 40-50% in [Alzheimer's disease](/diseases/alzheimers-disease) [brain](/brain-regions/brain)s, disrupting synaptic function
Sphingomyelin: Reduced in [Alzheimer's disease](/diseases/alzheimers-disease) membrane preparations, altering membrane fluidity

Connection to Other Mechanisms

Sphingolipid pathways intersect with multiple [Alzheimer's disease](/diseases/alzheimers-disease) therapeutic approaches:

Lysosomal dysfunction: [GCase](/proteins/gcase-glucocerebrosidase) mutations (GBA1) impair sphingolipid catabolism, linking to [lysosomal](/mechanisms/lysosomal-dysfunction) pathways addressed by Gain Therapeutics, Lysoway Therapeutics
Neuroinflammation: S1P receptor signaling drives [[microglia](/cell-types/microglia)](/cell-types/microglia) activation, overlapping with neuroinflammation category
Amyloid processing: Lipid raft composition directly affects alpha- and beta-secretase activity, linking to amyloid category
Mitochondrial dysfunction: Ceramide directly induces mitochondrial [apoptosis](/mechanisms/apoptosis-pathway) and mitophagy

Emerging Approaches

Sphingosine-1-Phosphate Receptor Modulators

S1P receptor modulators (inspired by fingolimod for multiple sclerosis) are being explored for [Alzheimer's disease](/diseases/alzheimers-disease):

S1P1 modulators: Reduce neuroinflammatory [[microglia](/cell-types/microglia)](/cell-types/microglia) activation
S1P5 modulators: Present on [[oligodendrocytes](/cell-types/oligodendrocytes)s](/cell-types/[oligodendrocytes](/cell-types/oligodendrocytes)s), potential for myelination support
Dual S1P1/S1P5 modulators: Combined anti-inflammatory and [oligodendrocytes](/cell-types/oligodendrocytes)-protective effects

Ceramide Kinase and Ceramide-1-Phosphate

Ceramide-1-phosphate (C1P) promotes cell proliferation and inflammation. Targeting [ceramide](/proteins/ceramide) kinase:

Ceramide kinase inhibitors: Reduce C1P-driven neuroinflammation
C1P analogs: Investigational tools to study C1P biology

Designer Ceramides and Sphingolipid Analogs

Synthetic sphingolipid analogs with modified properties:

Stable [ceramide](/proteins/ceramide) analogs: Resistant to ceramidase degradation for sustained signaling
Fluorescent sphingolipid probes: For imaging sphingolipid distribution in the [brain](/brain-regions/brain)
Cell-permeable [ceramide](/proteins/ceramide)s: For testing [neuroprotection](/therapeutics/neuroprotection) [ceramide](/proteins/ceramide) signaling

Research and Academic Centers

[Van Andel Institute](/organizations/van-andel-institute): Leading research on sphingolipid metabolism in neurodegeneration, [sphingosine kinase](/proteins/sphingosine-kinase) signaling, and [lipid raft](/mechanisms/lipid-raft-dysfunction) biology
University of Michigan: Research on ASM/[ceramide](/proteins/ceramide) pathways in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)
University of California San Diego: Ganglioside biology and synaptic function
Tokyo Metropolitan Institute: Sphingolipid metabolism in aging and neurodegeneration

Challenges and Opportunities

Challenges

Blood-[brain](/brain-regions/brain) barrier delivery: Many sphingolipid agents are large or poorly BBB-penetrant
Dose optimization: Ceramide has dual roles — too much triggers [apoptosis](/mechanisms/apoptosis-pathway), too little impairs protective signaling
Species specificity: Sphingolipid metabolism differs between rodents and humans, complicating preclinical translation
Biomarker development: Difficult to measure [brain](/brain-regions/brain) sphingolipid levels non-invasively
Off-target effects: Sphingolipid enzymes have multiple substrates and pleiotropic effects

Opportunities

Multi-mechanism targeting: Single agent can simultaneously reduce amyloid, neuroinflammation, and neuronal death
Biomarker availability: Plasma and CSF sphingolipid levels can serve as pharmacodynamic biomarkers
Combination potential: Sphingolipid modulators may enhance efficacy of amyloid antibodies, BACE inhibitors
Repurposing potential: Existing S1P modulators (fingolimod, siponimod) can be tested in [Alzheimer's disease](/diseases/alzheimers-disease) trials
Gene therapy: LNP-based delivery of sphingolipid-modifying genes offers sustained CNS targeting

Pipeline Overview

| Company | Lead Program | Target | Indication | Stage |
|---------|-------------|--------|------------|-------|
| Cyclo Therapeutics | Trappsol | Cyclodextrin | [Alzheimer's disease](/diseases/alzheimers-disease) | Phase 1 planning |
| Gain Therapeutics | GT-02287 | [GCase](/proteins/gcase-glucocerebrosidase) chaperone | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |
| Axxonis Pharma | Lead compound | CerS/SK inhibitors | [Alzheimer's disease](/diseases/alzheimers-disease) | Lead optimization |
| Accerise | Lead compound | Acid ceramidase | [Alzheimer's disease](/diseases/alzheimers-disease) | Lead optimization |
| Esperino | Lead compound | Ganglioside analog | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |
| Cerenis Therapeutics | CER-001 analog | Ceramide-[HDL](/proteins/hdl-particle) | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |
| 2seventy Bio | Platform | LNP-[siRNA](/technologies/sirna-delivery) | [Alzheimer's disease](/diseases/alzheimers-disease) | Platform |
| Orgenesis | Autologous cells | Cell therapy | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |
| Heqix Therapeutics | Lead compound | Lipid raft stabilizer | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |
| HAXXES | Anti-GD3 antibody | Ganglioside antibody | [Alzheimer's disease](/diseases/alzheimers-disease) | Preclinical |

References

[Cyclo Therapeutics Official Site](https://www.cyclotherapeutics.com)

[[Van Andel Institute](/organizations/van-andel-institute) - Sphingolipid Research](https://www.vai.org)

[Gain Therapeutics - [GCase](/proteins/gcase-glucocerebrosidase) Modulators](https://www.gaintherapeutics.com)

[Heqix Therapeutics](https://www.heqix.com)

[2seventy Bio LNP Platform](https://www.2seventybio.com)

Pathway Diagram

The following diagram shows the key molecular relationships involving ad-sphingolipid-ceramide-companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →